These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 16491518)

  • 1. [Oxaliplatin neurotoxicity].
    Gamelin L; Boisdron-Celle M; Morel A; Gamelin E
    Bull Cancer; 2006 Feb; 93 Suppl 1():S17-22. PubMed ID: 16491518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures.
    Gamelin E; Gamelin L; Bossi L; Quasthoff S
    Semin Oncol; 2002 Oct; 29(5 Suppl 15):21-33. PubMed ID: 12422305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical management of oxaliplatin-associated neurotoxicity.
    Grothey A
    Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S38-46. PubMed ID: 15871765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nerve excitability assessment in chemotherapy-induced neurotoxicity.
    Park SB; Lin CS; Kiernan MC
    J Vis Exp; 2012 Apr; (62):. PubMed ID: 22565594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of oxaliplatin-induced peripheral neuropathy.
    Saif MW; Reardon J
    Ther Clin Risk Manag; 2005 Dec; 1(4):249-58. PubMed ID: 18360567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxaliplatin-related neurotoxicity: how and why?
    Pasetto LM; D'Andrea MR; Rossi E; Monfardini S
    Crit Rev Oncol Hematol; 2006 Aug; 59(2):159-68. PubMed ID: 16806962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.
    Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
    Brain; 2009 Oct; 132(Pt 10):2712-23. PubMed ID: 19745023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative Sensory Testing at Baseline and During Cycle 1 Oxaliplatin Infusion Detects Subclinical Peripheral Neuropathy and Predicts Clinically Overt Chronic Neuropathy in Gastrointestinal Malignancies.
    Reddy SM; Vergo MT; Paice JA; Kwon N; Helenowski IB; Benson AB; Mulcahy MF; Nimeiri HS; Harden RN
    Clin Colorectal Cancer; 2016 Mar; 15(1):37-46. PubMed ID: 26337211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of calcium/ magnesium infusion in oxaliplatin-based chemotherapy for colorectal cancer patients.
    Kurniali PC; Luo LG; Weitberg AB
    Oncology (Williston Park); 2010 Mar; 24(3):289-92. PubMed ID: 20394142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer.
    Lersch C; Schmelz R; Eckel F; Erdmann J; Mayr M; Schulte-Frohlinde E; Quasthoff S; Grosskreutz J; Adelsberger H
    Clin Colorectal Cancer; 2002 May; 2(1):54-8. PubMed ID: 12453338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prophylactic effect of amifostine on oxaliplatin-related neurotoxicity in patients with digestive tract tumors].
    Lu P; Fan QX; Wang LX; Wang X; Zong H; Wang RL
    Ai Zheng; 2008 Oct; 27(10):1117-20. PubMed ID: 18851795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity.
    Park SB; Goldstein D; Lin CS; Krishnan AV; Friedlander ML; Kiernan MC
    J Clin Oncol; 2009 Mar; 27(8):1243-9. PubMed ID: 19164207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels.
    Grolleau F; Gamelin L; Boisdron-Celle M; Lapied B; Pelhate M; Gamelin E
    J Neurophysiol; 2001 May; 85(5):2293-7. PubMed ID: 11353042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer.
    Leonard GD; Wright MA; Quinn MG; Fioravanti S; Harold N; Schuler B; Thomas RR; Grem JL
    BMC Cancer; 2005 Sep; 5():116. PubMed ID: 16168057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcium and magnesium prophylaxis for oxaliplatin-related neurotoxicity: is it a trade-off between drug efficacy and toxicity?
    Khattak MA
    Oncologist; 2011; 16(12):1780-3. PubMed ID: 22128115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Reduction of oxaliplatin-related neurotoxicity by calcium and magnesium infusions].
    Muto O; Ando H; Ono T; Itagaki H; Kobayashi Y; Onuki M; Akashi T; Tanaka Y; Hanaoka T
    Gan To Kagaku Ryoho; 2007 Apr; 34(4):579-81. PubMed ID: 17431344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxaliplatin-safety profile: neurotoxicity.
    Grothey A
    Semin Oncol; 2003 Aug; 30(4 Suppl 15):5-13. PubMed ID: 14523789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxaliplatin-Induced Neuropathy: A Long-Term Clinical and Neurophysiologic Follow-Up Study.
    Kokotis P; Schmelz M; Kostouros E; Karandreas N; Dimopoulos MA
    Clin Colorectal Cancer; 2016 Sep; 15(3):e133-40. PubMed ID: 27038553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of oxaliplatin-induced neuropathy: a patient perspective.
    Bennett BK; Park SB; Lin CS; Friedlander ML; Kiernan MC; Goldstein D
    Support Care Cancer; 2012 Nov; 20(11):2959-67. PubMed ID: 22426503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Literature review and practical aspects on the management of oxaliplatin-associated toxicity.
    Hoff PM; Saad ED; Costa F; Coutinho AK; Caponero R; Prolla G; Gansl RC
    Clin Colorectal Cancer; 2012 Jun; 11(2):93-100. PubMed ID: 22154408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.